Cardiovascular diseases, considered the deadliest worldwide by the World Health Organization (WHO), lack effective therapies for regenerating cardiomyocytes. With their self-renewal and pluripotency capabilities, stem cell therapies are increasingly used in precision medicine. Induced pluripotent stem cells (iPSCs) are a promising alternative to embryonic stem cells. Good Manufacturing Practice (GMP) principles are not yet adapted for large-scale production of iPSCs. Additionally, the quality risk for iPSC products may not always be possible to eliminate, potentially jeopardizing the health of patients. This review aims to identify critical quality attributes (CQAs) for iPSC-derived cardiomyocytes (iPSC-CMs) for the development of cardiovascular therapy to ensure compliance with regulations and safety for patients. To attain these goals, the literature review was conducted with articles related to iPSCs and iPSC-CM therapies, legislation, and regulatory guidelines of the European Medicines Agency (EMA), Food and Drug Administration (FDA), and Pharmaceuticals and Medical Devices Agency (PMDA). In conclusion, additional regulations and guidelines are needed to monitor differentiation, maturation, and tumorigenicity. GMP-compliant cell banks and fast-track approval systems may increase accessibility for patients.
Impact statement
By identifying critical quality attributes for induced pluripotent stem cell (iPSC)-derived cardiomyocyte (iPSC-CM) therapy, this work has the potential to develop the field of regenerative medicine. Developing a high quality and safe product that meets Good Manufacturing Practice (GMP) principles and applicable regulations is crucial for the success of cell therapies. Additionally, the implementation of GMP-compliant cell banks and fast-track approval systems can significantly improve patient access to these treatments. Ultimately, this could lead to more effective treatments for cardiovascular disease, improving patient outcomes and quality of life. This work represents a significant step forward in the development of regenerative medicine and has the potential to significantly impact the field.
Get full access to this article
View all access options for this article.
References
1.
WiegandC, BanerjeeI. Recent advances in the applications of iPSC technology. Curr Opin Biotechnol, 2013; 60:5.
2.
ProwseAB, TimminsNE, YauTM, et al.Transforming the promise of pluripotent stem cell-derived cardiomyocytes to a therapy: Challenges and solutions for clinical trials. Can J Cardiol, 2014; 30(11):1335–1349.
NakahataT, OkanoH. Science Board, the Pharmaceuticals and Medical Devices Agency. Current perspective on evaluation of tumorigenicity of cellular and tissue-based products derived from induced pluripotent stem cells (iPSCs) and iPSCs as their starting materials [Cellular and Tissue-based Products Subcommittee Report published on August 20, 2013]. Available from: https://www.pmda.go.jp/files/000152599.pdf
5.
European Medicines Agency. EMEA/CHMP/410869/2006. Guideline on Human Cell-Based Medicinal Products. European Medicines Agency: London, 2008; p. 21.
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance). European Parliament, Council of the European Union, 2007; p. 13.
8.
Code of Federal Regulations Title 21—US Food and DrugAdministration. Part 1271 HumanCells, Tissues, and Cellular and Tissue-basedProducts. The FederalRegister. 2011.
9.
JarrellDK, VandersliceEJ, VeDepoMC, et al.Engineering myocardium for heart regeneration—Advancements, considerations, and future directions. Front Cardiovasc Med, 2020; 7:180.
10.
HallJE, HallME. Guyton and Hall Textbook of Medical Physiology, 14th ed. Elsevier: Philadelphia, PA, 2021; pp. 113–122.
11.
ParrottaEI, LucchinoV, ScaramuzzinoL, et al.Modeling cardiac disease mechanisms using induced pluripotent stem cell-derived cardiomyocytes: Progress, promises and challenges. Int J Mol Sci, 2020; 21:12.
12.
TawfikGM, DilaKAS, MohamedMYF, et al.A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health, 2019; 47:46.
13.
MazzolaM, Di PasqualeE. Toward cardiac regeneration: Combination of pluripotent stem cell-based therapies and bioengineering strategies. Front Bioeng Biotechnol, 2020; 8:5.
14.
RoweRG, DaleyGQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet, 2019; 20(7):377–388.
15.
MurataK, IkegawaM, MinatoyaK, et al.Strategies for immune regulation in iPS cell-based cardiac regenerative medicine. Inflamm Regen, 2020; 40:36.
16.
HuJ, WangJ. From embryonic stem cells to induced pluripotent stem cells-Ready for clinical therapy?. Clin Transplant, 2019; 33(6):6.
17.
VivesJ, Batlle-MoreraL. The challenge of developing human 3D organoids into medicines. Stem Cell Res Ther, 2020; 11:72.
DossMX, SachinidisA. Current challenges of iPSC-based disease modeling and therapeutic implications. Cells, 2019; 8(5):403–404.
20.
DashtbanM, PanchalingamKM, ShafaM, et al.Addressing manufacturing challenges for commercialization of iPSC-based therapies. Methods Mol Biol, 2020; 2286:179–198.
21.
TendeanM, OktavionoYH, SandraF. Cardiomyocyte reprogramming: A potential strategy for cardiac regeneration. Mol Cell Biomed Sci, 2017; 1:1–5.
22.
ApostolouE, StadtfeldM. Cellular trajectories and molecular mechanisms of iPSC reprogramming. Curr Opin Genet Dev, 2018; 52:77–85.
23.
LeeB, BorysBS, KallosMS, et al.Challenges and solutions for commercial scale manufacturing of allogeneic pluripotent stem cell products. Bioengineering (Basel), 2020; 7(2):6.
24.
BorysBS, SoT, ColterJ, et al.Optimized serial expansion of human induced pluripotent stem cells using low- density inoculation to generate clinically relevant quantities in vertical-wheel bioreactors. Stem Cells Transl Med, 2020; 9(9):1036–1052.
25.
PolancoA, KuangB, YoonS. Bioprocess technologies that preserve the quality of iPSCs. Trends Biotechnol, 2020; 38(10):1128–1140.
26.
BurnhamMP, HarveyR, SargeantR, et al.A scalable approach reveals functional responses of iPSC cardiomyocyte 3D spheroids. SLAS Discov, 2021; 26(3):352–363.
27.
LacoF, LamATL, WooTL, et al.Selection of human induced pluripotent stem cells lines optimization of cardiomyocytes differentiation in an integrated suspension microcarrier bioreactor. Stem Cell Res Ther, 2020; 11(1):118.
28.
Dos SantosFF, AndradePZ, Da SilvaCL, et al.Bioreactor design for clinical-grade expansion of stem cells. Biotechnol J, 2013; 8(6):644–654.
29.
European Medicines Agency. EMA/CAT/573420/2009. Reflection Paper on Clinical Aspects Related to Tissue Engineered Products. European Medicines Agency: London; 2014.
30.
European Medicines Agency. EMA/CAT/94295/2020. EMA Warns Against Using Unproven Cell-Based Therapies. European Medicines Agency: Amsterdam, 2020; p. 28.
31.
European Medicines Agency. Reflection Paper on Classification of Advanced Therapy Medicinal Products. European Medicines Agency: London, 2015; p. 21.
32.
European Medicines Agency. Reflection Paper on Stem Cell-Based Medicinal Products. European Medicines Agency: London, 2011; p. 14.
33.
Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products (Text with EEA relevance). EuropeanParliament, Council of the EuropeanUnion. 2009; p. 14.
34.
European Commission. Guidelines on Good Clinical Practice Specific to Advanced Therapy Medicinal Products. European Commission: Brussels, 2019; p. 10.
35.
BuikemaJW, LeeS, GoodyerWR, et al.Wnt activation and reduced cell–cell contact synergistically induce massive expansion of functional human iPSC-derived cardiomyocytes. Cell Stem Cell, 2020; 27(1):50–63.
36.
IrvineDJ, StachowiakAN, HoriY. Lymphoid tissue engineering: invoking lymphoid tissue neogenesis in immunotherapy and models of immunity. Semin Immunol, 2008; 20(2):137–146.
37.
SullivanS, FairchildPJ, MarshSG, et al.Haplobanking induced pluripotent stem cells for clinical use. Stem Cell Res, 2020; 49:102035.
38.
NakahataT, OkanoH. Proposal on Basic Principle to Quality Assurance of Cell Therapy (CT) Products. Pharmaceuticals and Medical Devices Agency, 2015; p. 14. Available from: https://www.pmda.go.jp/files/000209949.pdf [Last accessed: April14, 2023].
RehakovaD, SouralovaT, KoutnaI. Clinical-grade human pluripotent stem cells for cell therapy: Characterization Strategy. Int J Mol Sci, 2020; 21(7):2435.
41.
SullivanS, StaceyGN, AkazawaC, et al.Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med, 2018; 13(7):859–866.
42.
JhaBS, FarnoodianM, BhartiK. Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Stem Cells Transl Med, 2021; 10(2):198–208.
43.
MartinU. Therapeutic Application of Pluripotent Stem Cells: Challenges and Risks. Frontiers Media S.A.: Lausanne; 2017.
44.
ThomasD, CunninghamNJ, ShenoyS, et al.Human iPSCs in cardiovascular research: Current approaches in cardiac differentiation, maturation strategies, and scalable production. Cardiovasc Res, 2022; 118(1):20–36.
45.
MaruyamaY.Regulation of Regenerative Medicine in Japan. Pharmaceuticals and Medical Devices Agency; 2017. Available from: https://www.pmda.go.jp/files/000219466.pdf [Last accessed: April14, 2023].
46.
Japanese Pharmacopoeia 15thEdition, Vol. I. Society of Japanese Pharmacopoeia: Tokyo; 2007.
47.
CarmenJ, BurgerSR, McCamanM, et al.Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development. Regen Med, 2012; 7(1):85–100.
48.
MalihiG, NikouiV, ElsonEL. A review on qualifications and cost effectiveness of induced pluripotent stem cells (IPSCs)-induced cardiomyocytes in drug screening tests. Arch Physiol Biochem, 2023; 129(1):131–142.
49.
European Medicines Agency. Reflection Paper on Management of Clinical Risks Deriving from Insertional Mutagenesis. European Medicines Agency: London, 2013; p. 19.
50.
ItakuraG, KawabataS, AndoMY, et al.Fail-safe system against potential tumorigenicity after transplantation of iPSC derivatives. Stem Cell Rep, 2017; 8(3):673–684.
51.
ICH Harmonised Tripartide Guideline—Quality Risk Management Q9. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use: London; 2015.
52.
ShiZD, TchaoJ, WuL, et al. Precision Installation of a Highly Efficient Suicide Gene Safety Switch in Human Induced Pluripotent Stem Cells. John Wiley & Sons, Ltd.: New York; 2020.
53.
SchaafS, ShibamiyaA, MeweM, et al.Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One, 2011; 6:e26397; doi: 10.1371/journal.pone.0026397
54.
ParkS, LuiC, JungWH, at al. Mechanical Characterization of hiPSC-Derived Cardiac Tissues for Quality Control. John Wiley & Sons, Ltd.: New York; 2018.
55.
VolpatoV, WebberC. Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility. Dis Model Mech, 2020; 13(1):dmm042317.
56.
JehudaRB, ShemerY, BinahO. Genome Editing in Induced Pluripotent Stem Cells Using CRISPR/Cas9. Stem Cell Rev Rep, 2018; 14(3):323–336; doi: 10.1007/s12015-018-9811-3
57.
Guidance for Industry: Eligibility Determination for Donors of HumanCells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Food and Drug Administration; 2007.
58.
ICH Harmonised Tripartite Guideline Viral Safety Evaluation of Biotechnological Products Derived from Cell Lines of Human or Animal Origin Q5A (R1). In: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1999; p. 23.
59.
European Pharmacopoeia (Ph. Eur.) 10.0 ed., Vol. I. European Directorate for the Quality of Medicines & HealthCare (EDQM); 2019.
60.
ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 2016; p. 9.
61.
HeL, ChenX. Cardiomyocyte induction and regeneration for myocardial infarction treatment: Cell sources and administration strategies. Adv Health Mater, 2020; 9(22):e2001175.
62.
ICH Harmonised Tripartite Guideline Derivation and Characterisation of Cell Substracts Used for Production of Biotechnological/Biological Products Q5D Current Step 4 Version. In: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1997; p. 6.
63.
Raw Materials for the Production of Cell-Based and Gene Therapy Products Symposium. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe and the European Medicines Agency (EMA): Strasbourg, 2013; p. 3.
64.
SunX, WuJ, QiangB, et al.Transplanted microvessels improve pluripotent stem cell- derived cardiomyocyte engraftment and cardiac function after infarction in rats. Sci Transl Med, 2020; 12(562):eaax2992.
65.
RibeiroAJ, SchwabO, MandegarMA, et al.Multi-imaging method to assay the contractile mechanical output of micropatterned human iPSC-derived cardiac myocytes. Circ Res, 2017; 120(10):1572–1583.
66.
TsukamotoY, AkagiT, AkashiM. Vascularized cardiac tissue construction with orientation by layer-by-layer method and 3D printer. Sci Rep, 2020; 10(1):5484.
67.
O'SheaO, SteegR, ChapmanC, et al. Development and Implementation of Large-Scale Quality Control for the European Bank for Induced Pluripotent Stem Cells. Elsevier: United Kingdom; 2020.
68.
Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on Setting Standards of Quality and Safety for theDonation, ProcurementTesting, ProcessingPreservation, Storage and Distribution of Human Tissues andCells. European Parliament, Council of Europe, 2004; p. 31.
69.
ICH Harmonised Tripartite Guideline—Pharmaceutical Development Q8(R2). The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2009.
70.
ICH Harmonised Guideline General Considerations for Clinical Studies E8(R1). In: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Geneva, Switzerland; 2021; p. 6.
71.
De SousaPA, SteegR, KreiselB, et al. Hot Start to European Pluripotent Stem Cell Banking. Elsevier: United Kingdom; 2017.
72.
ZhangB, MontgomeryM, ChamberlainMD, et al.Biodegradable scaffold with built-in vasculature for organ-on-a-chip engineering and direct surgical anastomosis. Nat Mater, 2016; 15(6):669–678.
OmoleAE, FakoyaAOJ. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications. PeerJ, 2018; 6:e4370.
75.
Safety and Efficacy of Induced Pluripotent Stem Cell-Derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure (BioVAT-HF). ClinicalTrials.gov, 2020; p. 21 Available from: https://clinicaltrials.gov/ct2/show/NCT04396899?term=iPSC+cardiac&draw=2 [Last accessed: April 14, 2023].
76.
Safety and Efficacy of Induced Pluripotent Stem Cell-Derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure EU Clinical Trials Register. 2020; p. 4. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000885-39/DE#A [Last accessed: April13, 2023].
